At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 411 enrolled
Drug / intervention
20 mg VEC-162 +3 moredrug
Likely dose
20 mg VEC-162from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 and Matching Placebo in Healthy Male and Female Subjects With Induced Transient Insomnia
In Brief
A Phase 3 clinical trial evaluating 20 mg VEC-162, 50 mg VEC-162, and 2 other interventions for Insomnia. Completed, enrolled 411 participants across 19 sites.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInsomnia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedFeb 2006
Primary CompletionAug 2006
TodayJul 2026
First PostedFeb 13, 2006
Enrollment StartFeb 1, 2006
Primary CompletionAug 1, 2006
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 20.4 years ago
Interventions
20 mg VEC-162drug
20 mg VEC-162
50 mg VEC-162drug
50 mg VEC-162
100 mg VEC-162drug
100 mg VEC-162
Placebodrug
Placebo